Podcast: How Sandoz plans to harness its "golden decade" - Pharmaceutical Technology

Sandoz’s chief commercial officer discusses the company’s ambitions plans to have a biosimilar-driven growth engine by 2040. Sandoz’s chief commercial officer discusses the company’s ambitions plans to have a biosimilar-driven growth engine by 2040. Currently, Sandoz relies primarily on generics for its revenue, with the 13 biosimilars in its portfolio dwarfed by the number of generics. Credit: GlobalData. At its Capital Markets Day on 8 September, Sandoz revealed a new set of targets – part of a roadmap dubbed Bio100 – that could help it become the undisputed leader in the biosimilar industry within the decade. Harnessing what it calls…

Source: Pharmaceutical Technology